Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacy PrEP cluster randomized trial
PACTR202302662168727Phase 4Not yet recruiting
- Sponsor
- Jhpiego
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Jhpiego. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202302662168727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302662168727.